论文部分内容阅读
目的:应用替罗非班治疗急性冠脉综合征(acute coronary syndrome,ACS),以观察其对患者血清C-反应蛋白(C-reactive protein,CRP)的影响。方法:选择63例急性冠脉综合征患者分成观察组、对照组。入院后常规扩冠、抗凝、抗血小板聚集治疗,观察组同时给予替罗非班治疗。于治疗前后分别检测CRP,进行对比分析。结果:2组ACS患者经4周治疗后CRP下降(P<0.01)。与对照组比较,观察组血清CRP水平下降明显,尤以治疗后4周最为明显(P<0.01)。2组患者均未见出血并发症。结论:替罗非班能明显降低血清CRP,抑制斑块内炎症反应,有效改善ACS,且不增加出血的危险,适于临床应用。
Objective: To study the effect of tirofiban on acute coronary syndrome (ACS) in patients with acute coronary syndrome (ACS) to observe its effect on serum C-reactive protein (CRP). Methods: 63 patients with acute coronary syndrome were divided into observation group and control group. After admission, conventional crown expansion, anticoagulation, anti-platelet aggregation treatment, the observation group also given tirofiban treatment. Before and after treatment were detected CRP, comparative analysis. Results: The CRP in 2 ACS patients decreased after 4 weeks treatment (P <0.01). Compared with the control group, serum CRP levels in the observation group decreased significantly, especially at 4 weeks after the treatment (P <0.01). No bleeding complications occurred in either group. Conclusion: Tirofiban can significantly reduce serum CRP, inhibit plaque inflammation, effectively improve the ACS, and does not increase the risk of bleeding, suitable for clinical application.